Anticancer drugs: To the rescue?

By Daniel Jones. Nature reviews. Drug discovery, 2004

9,886 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

The epidermal growth factor receptor family: Biology driving targeted therapeutics (2008, background): “Three types of mutation have been defined: missense mutations causing L858R, G719X and L861Q, in frame deletions within exon 19, and insertions in exon 20 [155,162].”
Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer (2012, result): “Similar to HCC827 cells, we found (1) overexpression of AXL in the absence of EGFR T790M, pEGFR and increased pMET, (2) overexpression of the EMT marker vimentin, and (3) that inhibition of AXL by siRNA, MP-470 or XL880 restored sensitivity to concurrent erlotinib treatment in the H3255 ER sublines ”
Feedback regulation of EGFR signalling: decision making by early and delayed loops (2011, background): “For example, mutant forms of EGFR frequently detected in lung cancer are characterized by a basal, ligand-independent function, which is sufficient to weakly activate downstream signals but insufficient to recruit CBL to trigger receptor degradatio”